Does Lowering Resting Heart Rate With Drugs Actually Reduce Death Risk, or Just Look Better on a Chart?
The correlation between high RHR and death risk is well established. Whether pushing the number down with medication changes the outcome is a separate, much messier question.
This piece covers whether pharmacologically lowering resting heart rate, and whether tracking cumulative RHR over time versus a single reading, changes mortality outcomes in clinical trial and registry data. It does not cover lifestyle-based RHR reduction (exercise, sleep), which is a separate mechanism covered elsewhere on this site.
Elevated resting heart rate is one of the most consistently replicated mortality predictors in cardiology, but that correlation doesn't automatically mean actively lowering RHR with medication reduces death risk. Four recent studies complicate the simple 'lower is better' framing. A German multicenter registry found resting heart rate measured in ordinary clinical practice had no prognostic relevance for one-year mortality in ICD and CRT-D recipients, a population where RHR is a commonly cited target. Meanwhile, three other studies, in a hypertension trial, in heart failure patients, and in atrial fibrillation patients, found that cumulative RHR load or longitudinal RHR trajectory tracked over months predicted mortality and cardiovascular events more consistently than any single reading. Together, these findings suggest that whether an isolated 'get your RHR down' target is even the right one is a genuinely open question, separate from whether sustained RHR load over time matters, which the evidence supports more consistently.
A single reading that didn't predict anything
The German DEVICE registry study is the most direct test of the simple version of this question: does a clinically measured resting heart rate above 70 beats per minute carry elevated one-year mortality risk in a population where RHR is specifically discussed as a treatment target. In 1,589 patients with implantable cardioverter-defibrillators or cardiac resynchronization therapy defibrillators, one-year all-cause mortality was statistically identical between the RHR-70-or-under group and the RHR-over-70 group, 5.4% in both.
That's a real null result in a real, clinically relevant population, not a case of insufficient data. It directly challenges the assumption that a single RHR reading, taken in an ordinary clinical visit, functions as a reliable mortality signal in every cardiac population.
4 studies
- In 1,589 ICD/CRT-D recipients in the German DEVICE registry, one-year all-cause mortality was statistically identical (5.4% vs. 5.4%) between patients with resting heart rate at or under 70 bpm and those above it, showing no prognostic relevance for a single clinically measured RHR reading in this population.
- In a post hoc analysis of the STEP trial (7,517 older hypertensive patients), cumulative resting heart rate load, calculated across repeated measurements at 0, 3, 6, 9, and 12 months, showed a U-shaped relationship with cardiovascular events, both the highest and lowest cumulative RHR quartiles carried elevated risk, though no such trend was observed for all-cause mortality specifically.
- Pooling data from five randomized controlled trials (BEST, GUIDE-IT, HF-ACTION, RELAX, TOPCAT) totaling 5,428 heart failure patients in sinus rhythm, cumulative resting heart rate load outperformed baseline heart rate, mean heart rate, and other single-point HR measures at predicting major adverse cardiac events, cardiovascular death, and all-cause death.
- In 3,921 atrial fibrillation patients from the AFFIRM study followed longitudinally, mean resting heart rate at or above 80 bpm was associated with roughly double the mortality risk (adjusted hazard ratio 2.01), and RHR trajectory patterns tracked over time, not single readings, defined the risk groups.
A moving target, not a fixed number
The pattern across the STEP trial, the pooled heart failure analysis, and the AFFIRM data points in the same direction: what predicts outcomes is the sustained pattern of resting heart rate over months, cumulative load or trajectory, rather than wherever a single number happens to land on a given clinic visit. The heart failure pooled analysis makes this explicit, cumulative RHR load beat baseline heart rate, mean heart rate, and every other single-point measure at predicting every outcome tested.
That reframes the practical question. It's not simply 'is my RHR under 70' but something closer to 'how much time has my heart rate spent elevated over the past several months,' a genuinely different, more longitudinal way of thinking about the same measurement, and one a wrist-worn device that tracks RHR daily is arguably better positioned to capture than an occasional clinical reading.
The STEP trial's U-shaped finding is a real complication worth sitting with: both unusually high and unusually low cumulative resting heart rate carried elevated cardiovascular event risk in that hypertensive population, which cuts against treating 'lower is always better' as a safe default.
How this differs from the site's existing trend-recovery coverage
The existing resting heart rate trend as a recovery indicator piece is about short-term readiness, day-to-day or week-to-week RHR shifts as a signal of overtraining, illness, or poor sleep. This piece is a distinct, longer-horizon question: whether sustained RHR load, tracked over months, functions as a genuine mortality-risk signal, and whether actively lowering RHR with medication changes that risk. Those are related uses of the same underlying number operating on very different timescales.
Common questions
Does taking a heart-rate-lowering drug reduce mortality risk?
The evidence is mixed and population-dependent. In one large registry of ICD/CRT-D recipients, a single RHR reading above 70 bpm carried no elevated one-year mortality risk at all. In heart failure and atrial fibrillation populations, sustained RHR load tracked over months showed a clearer, more consistent relationship with mortality and cardiovascular events than any single reading.
Is a single RHR reading at a doctor's visit a reliable mortality predictor?
Not necessarily. The German DEVICE registry study found no difference in one-year mortality between ICD/CRT-D patients with RHR at or under 70 bpm versus above it, a real null result in a population where RHR is commonly discussed as a treatment target.
What is cumulative RHR load?
It's a measure that accounts for both how high resting heart rate runs and how long it stays elevated over time, calculated across repeated measurements rather than a single reading. Multiple studies found it outperformed single-point RHR measures at predicting cardiovascular outcomes.
Is lower resting heart rate always better?
Not according to the STEP trial's post hoc analysis, which found a U-shaped relationship between cumulative RHR and cardiovascular events in older hypertensive patients, meaning both unusually high and unusually low cumulative RHR carried elevated risk.
Sources
- Resting heart rate assessed within clinical practice demonstrates no prognostic relevance for defibrillator recipients in the German DEVICE registry.
- Relationships Between Cumulative Resting Heart Rate and the Incidence of Cardiovascular Events and All-Cause Mortality - Post Hoc Analysis of STEP Trial Data.
- Cumulative resting heart rate load and cardiovascular risk in patients with heart failure in sinus rhythm.
- Longitudinal Association Between Resting Heart Rate and Mortality in Atrial Fibrillation.